Dealing With MedImmune

Law360, New York (March 13, 2007, 12:00 AM EDT) -- In MedImmune v. Genentech, 127 S. Ct. 764 (2007), the Supreme Court held that a patent licensee does not have to repudiate the license in order to file a declaratory judgment action challenging the validity of the underlying patent.

Many observers believe that this decision will fundamentally alter the negotiating positions of prospective licensors and licensees. Until MedImmune, a licensee could not make a validity challenge without first repudiating the license, refusing to pay royalties and infringing the patent.

The licensee would then face major risks...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.